Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of chemotherapeutic agents and improved patient selection for autologous stem cell transplantation (ASCT); however, for patients who are diagnosed at later stages or who are ineligible for ASCT the prognosis is poorer. Recently, the introduction of daratumumab has shown promising results for patients with both newly diagnosed and relapsed/refractory amyloidosis and there have been a number of Phase II/III trials aiming to help guide treatment decision-making and improve patient outcomes.
In today’s podcast, Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of key updates in the treatment landscape of amyloidosis, as presented at the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
The AML Sessions: highlights from ASCO/EHA 2021
EHA 2021: key trial updates in myeloma
Key updates on CAR-T therapy for ALL
The Myeloma Sessions: post-COMY 2021 myeloma patients session
EHA 2021: MRD in myeloma
Latest updates on CAR-T therapy for CLL
The Myeloma Sessions: post-COMy 2021 roundtable
Focus on ALL: treating older patients, Ph-like ALL & post-transplant interventions
MDS Session: Women in Science
Key updates on CAR-T & cellular therapy for AML
The MDS Sessions: highlights from ASH 2020
The Transplant Sessions: ASH 2020 highlights
The Lymphoma Sessions: ASH 2020 highlights
Latest updates in Hodgkin lymphoma from ISHL HL 2021
The Myeloma Sessions: Post-ASH 2020 UK Discussion
The Post-EBMT for Trainees VJSessions
Post-ASH Amyloidosis Session from VJHemOnc
The Post EBMT VJSessions from VJHemOnc
Post-EBMT Highlights in Acute Myeloid Leukemia
The CLL Sessions: highlights from ASH 2020
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive